Deerfield Management
FATE icon

Deerfield Management’s Fate Therapeutics FATE Stock Holding History

Deerfield Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,555,871
Closed -$5.87M – 129
2024
Q4 		$5.87M Hold
3,555,871
– – 0.11% 69
2024
Q3 		$12.4M Hold
3,555,871
– – 0.19% 64
2024
Q2 		$11.7M Buy
3,555,871
+1,365,463
+62% +$5.98M 0.19% 64
2024
Q1 		$16.1M Buy
+2,190,408
New +$13.6M 0.28% 59
2021
Q4 		– Sell
-362,000
Closed -$21.5M – 134
2021
Q3 		$21.5M Buy
362,000
+58,000
+19% +$4.55M 0.42% 66
2021
Q2 		$26.4M Hold
304,000
– – 0.47% 71
2021
Q1 		$25.1M Buy
+304,000
New +$29.1M 0.53% 66
2020
Q4 		– Sell
-668,067
Closed -$41.5M – 28
2020
Q3 		$26.7M Sell
668,067
-245,708
-27% -$8.58M 0.65% 50
2020
Q2 		$31.4M Sell
913,775
-703,218
-43% -$21M 0.91% 36
2020
Q1 		$35.9M Sell
1,616,993
-385,612
-19% -$9.75M 1.14% 29
2019
Q4 		$39.2M Buy
2,002,605
+49,708
+3% +$789K 1.25% 28
2019
Q3 		$30.3M Buy
1,952,897
+250,000
+15% +$4.79M 1.24% 24
2019
Q2 		$34.6M Hold
1,702,897
– – 1.24% 23
2019
Q1 		$29.9M Buy
1,702,897
+48,032
+3% +$758K 1.15% 28
2018
Q4 		$21.2M Buy
1,654,865
+481,248
+41% +$6.71M 0.85% 42
2018
Q3 		$19.1M Buy
+1,173,617
New +$13.9M 0.68% 49

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Deerfield Management's FATE Position: Q1 2025 in Review

Deerfield Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 3,555,871 shares — an estimated $5.87M sold.

Deerfield Management first reported a position in FATE in Q3 2018 and held it in 16 quarters. The position peaked at $39.2M in Q4 2019. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Deerfield Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Deerfield Management sold 3,555,871 Fate Therapeutics shares in Q1 2025, an estimated $5.87M.
  • Deerfield Management first reported a position in Fate Therapeutics in Q3 2018 and held it in 16 quarters.
  • Deerfield Management's Fate Therapeutics position peaked at $39.2M in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Deerfield Management's 13F filing for Q1 2025, filed 15 May 2025.